image dons

je fais un don

Indirect comparison of the efficacy and safety of alirocumab and evolocumab : a systematic review and network meta-analysis

Colloquium "Rythme et conduction" (23 avril 2024)
Programme et inscription, c'est ici !

Bourses ACTION 2024 - Prix de Recherche JP Collet et Y Grosgogeat - PHRA 2024
M2, thèse de sciences, mobilité et soins infirmiers : deadline 15 mars - PHRA : deadline 30 mars

La Grande Journée du Coeur - Rendez-vous dans un cadre exceptionnel : l'Eglise Saint-Louis de la Pitié-Salpêtrière le jeudi 27 juin 2024
A vos agendas !

European Heart Journal - Cardiovascular Pharmacotherapy 2021 May 23;7(3):225-235


Article disponible en consultant le site

Auteurs

Guedeney P, Sorrentino S, Giustino G, Chapelle C, Laporte S, Claessen BE, Ollier E, Camaj A, Kalkman DN, Vogel B, De Rosa S, Indolfi C, Lattuca B, Zeitouni M, Kerneis M, Silvain J, Collet JP, Mehran R, Montalescot G.

Abstract

Background

Although alirocumab and evolocumab have both been associated with improved outcomes in patients with dyslipidaemia or established atherosclerotic cardiovascular disease, data on their respective performances are scarce.

Aims

This study aimed at providing an indirect comparison of the efficacy and safety of alirocumab vs. evolocumab.

Methods

We conducted a systematic review and network meta-analysis of randomized trials comparing alirocumab or evolocumab to placebo with consistent background lipid-lowering therapy up to November 2018. We estimated the relative risk (RR) and the 95% confidence intervals (CIs) using fixed-effect model in a frequentist pairwise and network meta-analytic approach.

Results

A total of 30 trials, enrolling 59 026 patients were included. Eligibility criteria varied significantly across trials evaluating alirocumab and evolocumab. Compared with evolocumab, alirocumab was associated with a significant reduction in all-cause death (RR 0.80, 95% CI 0.66-0.97) but not in cardiovascular death (RR 0.83, 95% CI 0.65-1.05). This study did not find any significant differences in myocardial infarction (RR 1.15, 95% CI 0.99-1.34), stroke (RR 0.96, 95% CI 0.71-1.28), or coronary revascularization (RR 1.13, 95% CI 0.99-1.29) between the two agents. Alirocumab was associated with a 27% increased risk of injection site reaction compared to evolocumab; however, no significant differences were found in terms of treatment discontinuations, systemic allergic reaction, neurocognitive events, ophthalmologic events, or new-onset of or worsening of pre-existing diabetes.

Conclusions

Alirocumab and evolocumab share a similar safety profile except for injection site reaction. No significant differences were observed across the efficacy endpoints, except for all-cause death, which may be related to the heterogeneity of the studied populations treated with the two drugs.

Autres actualités

+

01/10/2023


Rationale and design of the ARAMIS trial: Anakinra versus pl...

Arch Cardiovasc Dis. 2023 Oct;116(10):460-466
+

01/09/2023


Comparison of three echo-guidance techniques in percutaneous...

Arch Cardiovasc Dis. 2023 Sep 29:S1875-2136(23)00171-7